128 related articles for article (PubMed ID: 24853767)
1. Structure-based de novo design and identification of D816V mutant-selective c-KIT inhibitors.
Park H; Lee S; Lee S; Hong S
Org Biomol Chem; 2014 Jul; 12(26):4644-55. PubMed ID: 24853767
[TBL] [Abstract][Full Text] [Related]
2. Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.
Lee S; Lee H; Kim J; Lee S; Kim SJ; Choi BS; Hong SS; Hong S
J Med Chem; 2014 Aug; 57(15):6428-43. PubMed ID: 25004409
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products.
Park H; Lee S; Hong S
J Nat Prod; 2016 Feb; 79(2):293-9. PubMed ID: 26807861
[TBL] [Abstract][Full Text] [Related]
4. Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design.
Park H; Hong S; Kim J; Hong S
J Am Chem Soc; 2013 Jun; 135(22):8227-37. PubMed ID: 23679864
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.
Ravez S; Arsenlis S; Barczyk A; Dupont A; Frédérick R; Hesse S; Kirsch G; Depreux P; Goossens L
Bioorg Med Chem; 2015 Nov; 23(22):7340-7. PubMed ID: 26526740
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Vendôme J; Letard S; Martin F; Svinarchuk F; Dubreuil P; Auclair C; Le Bret M
J Med Chem; 2005 Oct; 48(20):6194-201. PubMed ID: 16190746
[TBL] [Abstract][Full Text] [Related]
7. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Keretsu S; Ghosh S; Cho SJ
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146
[TBL] [Abstract][Full Text] [Related]
8. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors.
Ding L; Tang F; Huang W; Jin Q; Shen H; Wei P
Bioorg Med Chem Lett; 2013 Oct; 23(20):5630-3. PubMed ID: 23999040
[TBL] [Abstract][Full Text] [Related]
10. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.
Porter J; Lumb S; Franklin RJ; Gascon-Simorte JM; Calmiano M; Riche KL; Lallemand B; Keyaerts J; Edwards H; Maloney A; Delgado J; King L; Foley A; Lecomte F; Reuberson J; Meier C; Batchelor M
Bioorg Med Chem Lett; 2009 May; 19(10):2780-4. PubMed ID: 19369077
[TBL] [Abstract][Full Text] [Related]
12. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
13. Design of potent IGF1-R inhibitors related to bis-azaindoles.
Nemecek C; Metz WA; Wentzler S; Ding FX; Venot C; Souaille C; Dagallier A; Maignan S; Guilloteau JP; Bernard F; Henry A; Grapinet S; Lesuisse D
Chem Biol Drug Des; 2010 Aug; 76(2):100-6. PubMed ID: 20545947
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
15. Computational design and discovery of nanomolar inhibitors of IκB kinase β.
Park H; Shin Y; Choe H; Hong S
J Am Chem Soc; 2015 Jan; 137(1):337-48. PubMed ID: 25513719
[TBL] [Abstract][Full Text] [Related]
16. Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.
Richters A; Ketzer J; Getlik M; Grütter C; Schneider R; Heuckmann JM; Heynck S; Sos ML; Gupta A; Unger A; Schultz-Fademrecht C; Thomas RK; Bauer S; Rauh D
J Med Chem; 2013 Jul; 56(14):5757-72. PubMed ID: 23773153
[TBL] [Abstract][Full Text] [Related]
17. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.
Liang Z; Zhang D; Ai J; Chen L; Wang H; Kong X; Zheng M; Liu H; Luo C; Geng M; Jiang H; Chen K
Bioorg Med Chem Lett; 2011 Jun; 21(12):3749-54. PubMed ID: 21561768
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
19. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
[TBL] [Abstract][Full Text] [Related]
20. Systematic Computational Design and Identification of Low Picomolar Inhibitors of Aurora Kinase A.
Park H; Jung HY; Mah S; Hong S
J Chem Inf Model; 2018 Mar; 58(3):700-709. PubMed ID: 29401391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
